Inmed Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
InMed Pharmaceuticals Inc. filed an amendment to its annual report, providing detailed disclosures on executive compensation, corporate governance, and director independence for the fiscal year ended June 30, 2025.
NASDAQ
InMed Pharmaceuticals Inc. reported its fiscal year 2025 results, highlighting progress in its Alzheimer's and dry AMD drug candidates, alongside revenue growth in its BayMedica segment, despite ongoing operating losses and a going concern doubt.
NASDAQ
InMed Pharmaceuticals Inc. releases its annual report, highlighting advancements in its drug development programs and providing a financial overview for the fiscal year ended June 30, 2024.